Polaryx Therapeutics, Inc. PLYX
Polaryx Therapeutics, Inc. (Nasdaq: PLYX) is a rare genetic drug developer. Its lead program, PLX-200 (gemfibrozil), is in Phase 2 for Lysosomal storage disorders (CLN2, CLN3, Krabbe, Sandhoff). Its next catalyst on record is PLX-200: Initiation of SOTERIA Phase 2 proof-of-concept basket trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PLX-200 — Initiation of SOTERIA Phase 2 proof-of-concept basket trial (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PLX-200 (SOTERIA basket trial) | CLN2, CLN3, Krabbe disease, Sandhoff disease | small molecule | Phase 2 |
| PLX-300 (cinnamic acid) | GM2 gangliosidosis, Krabbe, Niemann-Pick A/B | small molecule | Pre-clinical |
| PLX-100 (PLX-200 + vitamin A) | Lysosomal storage disorders (CLN2 ODD) | small molecule | Pre-clinical |
| PLX-400 | Lysosomal storage disorders | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.